Non Small-Cell Lung Cancer Metastatic to the Mitral Valve: Case Report and Review of the Literature

Daniel J. Axelson, Natalie P. Kreitzer, Gregory J. Fermann

Department of Emergency Medicine, University of Cincinnati, Cincinnati, USA
Email: kreitzne@ucmail.uc.edu

Received 15 May 2014; revised 14 June 2014; accepted 13 July 2014

Copyright © 2014 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/

Abstract

In 2008, 1.6 million new cases of lung cancer were diagnosed worldwide, representing 13% of all cancer cases for the year, and in 2010, 19% of cancer deaths were attributed to lung cancer. Though lung cancer frequently metastasizes to the adrenal glands, bone, brain, liver, and other lung, it infrequently metastasizes to the heart. Here, we report a case of lung cancer metastatic to the mitral valve.

Keywords
Lung Cancer, Myocardial Infarction

1. Introduction

MK was a 34-year-old African male who presented to the emergency department with the chief complaint of abdominal pain. He rated his pain at 8/10 in the center of his abdomen, with radiation into the right lower quadrant. His last normal bowel movement was several days ago. He had non-bloody, non-bilious emesis which he attributed to concurrent treatment for Stage 4 non-small cell lung cancer. He denied having a fever, diarrhea, shortness of breath, coughing, chest pain, or sore throat. He had a recent presentation and subsequent hospital admission for the same complaint two weeks prior to presentation. At that time, a CT scan of the abdomen and pelvis with IV and PO contrast had been negative. He had no prior history of abdominal surgeries. He had no known drug allergies. His medications were analgesics, anti-emetics, and the chemotherapeutic agent Erlotinib. He had emigrated from Senegal to the US several years ago.

On examination, the patient was ill appearing and cachectic. He was tachycardic with a heart rate in the 120 s to 130 s. Vital signs were otherwise unremarkable. His abdominal exam revealed tenderness to palpation, re-
bound and involuntary guarding in the mid epigastric region, right upper quadrant, and right lower quadrant. A bedside ultrasound of his right upper quadrant, performed by the emergency physician, demonstrated a normal appearing gallbladder, no pericholecystic fluid, no gallbladder wall thickening, and a normal common bile duct.

Pertinent labs revealed a WBC of 27,000 with 4% bands, a lactate of 2.0 mmol/L. Abdominal plain films demonstrated a normal bowel gas pattern. A CT scan of the abdomen and pelvis with IV and PO contrast demonstrated a subtle peripheral hypo-density within the spleen and several new wedge shaped areas of low attenuation within both kidneys. These were concerning for infarcts of an embolic source, and were not present on the CT scan two weeks prior.

Blood cultures were obtained and the patient was administered IV Vancomycin and Gentamycin for presumed endocarditis. An EKG (electrocardiogram) performed as part of his workup for endocarditis demonstrated ST elevations in V3, V4, V5, and V6 (Figure 1). The Cardiology team was consulted regarding further diagnostic and therapeutic options. A bedside echo in the emergency department demonstrated distal anterior and apical hypokinesis, no pericardial fluid, and no gross valvular abnormalities. Cardiac Troponin I was elevated at 23.62 ng/dl. Given the clinical scenario, the cardiology team elected to proceed with left heart catheterization.

2. Inpatient Course

The patient was taken to the cath lab, where he was found to have a 100% mid LAD occlusion. Debris was suctioned from his coronary vessels. After thrombus and debris aspiration, TIMI 2-3 flow was established and no stents were deployed. During the procedure a second coronary embolic event was visualized into one of the diagonal arteries. The aspirated thrombotic material was sent to the lab, and ultimately found to be consistent with clot. A gram stain of the material was negative for bacteria or fungus. Concurrent medical therapy post procedure did not initially involve anticoagulation. The patient was felt to have a high risk of bleeding with septic emboli, hemoptysis, and a small pericardial effusion. The effusion was not hemodynamically compromising, but was likely hemorrhagic. The oncology team, however, had concerns that the patient’s presentation was consi-
tent with low grade DIC (thrombotic type), and he was started on a full dose unfractionated heparin infusion following a negative non-contrast head CT.

A repeat 2D echocardiogram demonstrated a globular mass associated with the lateral aspect of the anterior and posterior mitral leaflets (A1, P1), which likely represented a metastatic mass (Figure 2). There was mild mitral regurgitation as well. The left ventricle had severely reduced systolic function, with an ejection fraction of 30% - 35%, diffuse hypo-kinesis, and Grade 1 diastolic dysfunction. There was a small pericardial effusion present as well. The clinical picture suggested tumor embolization to the coronary arteries, spleen and kidneys. This was deduced based on the patient’s blood cultures remaining negative throughout his hospital course. Although the patient initially wanted to continue treatment for his malignancy, therapeutic options were limited given the extent of his disease. Hospice care was arranged and the patient passed away shortly.

3. Literature Review

In 2008, 1.6 million new cases of lung cancer were diagnosed worldwide, representing 13% of all cancer cases for the year [1]. In 2010, lung cancer associated deaths rose to account for 19% of all cancer deaths [2]. The vast majority of lung cancers (~80%) is non-small cell lung cancers (NSCLC) [3], and NSCLC patients present with locally advanced or metastatic disease more than 65% of the time [4]. The late manifestations of cardiac disease secondary to cancer treatments have been more rigorously documented [5]. However, much of what is seen of the different presentations related to NSCLC metastases comes from case reports in the literature. Case reports have documented the more acute, ischemic complications of metastatic NSCLC. Sadat et al. report a case of peripheral limb ischemia from primary lung neoplasm that had migrated to the heart [6]. The phenomenon of cardiac metastasis in NSCLC is very rare but has been documented in the literature even as a primary presentation of lung neoplasm [7]. In all cancer patients, somewhere between 10% and 15% of patients have been found
to have cardiac metastases on pathologic examination [8]. This number holds true with NSCLC, which has been estimated to invade the cardiac atria in up to 10% of cases [9]. To our knowledge, however, the specific incidence of mitral valve involvement with NSCLC is unknown. Cardiac metastases are found in advanced cancers and lead to significant morbidity. Liang et al. report a case of disseminated microvascular pulmonary tumor emboli leading to pulmonary hypertension and sudden cardiac death [10]. Leeies and Weldon report a case of occult malignancy first presenting as ST segment elevation myocardial infarction (STEMI) with cardiac tamponade [11]. They appropriately call for the expanded use of ultrasound as a diagnostic modality in the evaluation of select cardiac patients in the ED.

Although cardiac metastases are rare, they are most commonly noted in lymphoma, leukemia, lung cancer, esophageal cancer, breast cancer, and melanoma [12]. In our patient’s case, his atrial mass was thought to represent tumor that seeded from venous flow of the pulmonary vascular system into the heart. This was based on his echo images (shown below), persistently negative blood cultures, and pathology reports of extracted thrombus from the left anterior descending artery that was consistent with fibrin. Treatment of atrial invasion by NSCLC has been described in case reports to include radiotherapy and pneumonectomy with atrial resection [9] [13] [14]. However, cardiac involvement portends poor outcomes in NSCLC, with median survival after treatment with atrial resection reported at 25 months [13]. We have found no description of the treatment of non-small cell lung cancer metastatic to the mitral valve in the literature.

Given the high likelihood of embolic complications from the valvular mass, surgery was presented as a treatment option for our patient. He elected not to pursue aggressive treatment for his condition, opting instead for home hospice care. This case represents an unusual presentation of cardiac involvement in NSCLC.

References


http://dx.doi.org/10.1016/j.lungcan.2010.12.022

http://dx.doi.org/10.1016/j.annemergmed.2010.08.011


http://dx.doi.org/10.1016/j.athoracsur.2004.01.023

Scientific Research Publishing (SCIRP) is one of the largest Open Access journal publishers. It is currently publishing more than 200 open access, online, peer-reviewed journals covering a wide range of academic disciplines. SCIRP serves the worldwide academic communities and contributes to the progress and application of science with its publication.

Other selected journals from SCIRP are listed as below. Submit your manuscript to us via either submit@scirp.org or Online Submission Portal.